Strata Critical Medical Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Strata Critical Medical Inc (SRTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Strata Critical Medical Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 212M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+37.0% annualized vs trailing 12 months).
- Scale: Strata Critical Medical Inc ranks #88 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Strata Critical Medical Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SRTA Sales vs. its Competitors, Q2 2026
Strata Critical Medical Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 2.4% for Strata Critical Medical Inc. Strata Critical Medical Inc's share of combined industry revenue moved from 0.07% to 0.06%, a loss of 0.01 percentage points.
Strata Critical Medical Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Strata Critical Medical Inc | Yes | No | No | Yes |
| High-Confidence Competitors (1) | - | |||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 37.50 % (3 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SRTA Stock Performance relative to its Competitors
SRTA Stock Performance relative to High-Confidence Competitors
SRTA Stock Performance relative to Similar-Size Competitors
SRTA Stock Performance relative to Similar Growth & Profitability Competitors
Strata Critical Medical Inc's Comment on Competition and Industry Peers
Strata Critical Medical Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Blade | Named by the company | 85% |
| Uber Technologies, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Strata Critical Medical Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Strata Critical Medical Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Strata Critical Medical Inc | Logistics 66.53 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).